Our data demonstrate that miR-125b act as an oncogene, whereas A20 act as a tumor suppressor in NPC, and suggests that targeting miR-125b/A20/NF-κB signaling axis is a promising approach for NPC patients with high miR-125b expression. Here, TNFAIP3 is linked to nasopharyngeal carcinoma.